Botswana's diamond giant slashes output as demand falls
Debswana, a joint venture between the government and global mining giant De Beers, saw its sales revenue drop by almost 50% last year.
Botswana is the world's largest producer of diamonds by value. The industry accounts for a quarter of the country's total annual income (GDP), according to the International Monetary Fund.
On Friday, Debswana said production this year is being scaled back to 15 million carats - approximately a 40% decrease from its output in 2023.
The company, which accounts for around 90% of Botswana's diamond sales expects this reduced output will lead to "significant cost savings" across areas like fuel and electricity.
In a statement, Debswana said it continued to "prudently navigate the challenging market conditions" citing low demand and "emerging pressures such as US-imposed tariffs".
The global market for mined diamonds has been experiencing a decline since 2023, partly due to the availability of lab-grown alternatives.
In response to this downturn, Debswana paused production at its flagship Jwaneng mine, as well as its Orapa mines, last month. Each mine will be closed for three months in total.
The southern African country has for decades been trying to shift its economy away from being dependent on diamond sales, to varying degrees of success.
Although successive governments have boosted sectors such as tourism, finance and the mining of minerals such as copper, diamond sales still make up three-quarters of Botswana's foreign exchange earnings.
This income is likely to be hit by Debswana's decision to temporarily close its mines.
The company has stressed that no involuntary job cuts are planned, although it continues to offer voluntary redundancy.
As a result of the sustained downturn in the global diamond industry, Botswana will cut its 2025 economic growth forecast to almost zero, a senior finance official was quoted as saying by the Reuters news agency.
World's second-largest diamond found in Botswana
How friends became foes in Africa's diamond state
'Proud to be young' - Beauty queen, lawyer and Botswana's youngest cabinet minister
Go to BBCAfrica.com for more news from the African continent.
Follow us on Twitter @BBCAfrica, on Facebook at BBC Africa or on Instagram at bbcafrica
Africa Daily
Focus on Africa
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Tech shares lift Wall St futures on tariff exemption hopes
(Reuters) -U.S. stock index futures rose on Thursday, pointing to fresh gains on Wall Street, on signs that major technology companies will avoid President Donald Trump's latest tariffs on chip imports. Apple's shares climbed 3.2% in premarket trading, having risen 5.1% and led gains on Wall Street in the prior session, after Trump said the iPhone maker will invest an additional $100 billion in the U.S., bringing its total commitment to $600 billion over the next four years. Trump also announced a tariff of about 100% on imports of semiconductors but said it would not apply to companies that are manufacturing in the U.S. or have committed to do so. Shares of chipmakers including Nvidia, Advanced Micro Devices and Intel rose in the range of 1.2% to 2.5%. At 06:16 a.m. ET, S&P 500 E-minis were up 53.75 points, or 0.84%, Nasdaq 100 E-minis were up 197 points, or 0.84%, and Dow E-minis were up 274 points, or 0.62%. The president's higher tariffs of 10% to 50% on dozens of trading partners took effect on Thursday. Still, expectations of policy easing by the Federal Reserve - sparked by some disappointing economic data, particularly the July payrolls report - as well as optimism around AI spending by companies have kept markets near record highs. Following the latest jobs data, traders have almost fully priced in a 25 basis point rate cut in September and expect at least two rate cuts this year, according to the CME Group's FedWatch tool. Weekly jobless claims data, due at 08:30 a.m. ET, could offer fresh clues on the health of the labor market and shift rate cut expectations. Investors are also watching for Trump's interim replacement for Fed Governor Adriana Kugler in the coming days, amid expectations that the nominee would be a policy dove who will likely favor bringing interest rates lower. Kugler's resignation leaves an opening at the seven-member Fed Board led by Chair Jerome Powell, who Trump has repeatedly criticized for not cutting borrowing costs. Powell's tenure is due to end in May 2025. Second-quarter earnings barrage continued at full throttle. DoorDash topped revenue estimates and forecasted a stronger-than-expected gross merchandise value for the current quarter. Its shares jumped 8.6%. Lyft's quarterly revenue miss took its stock down 2.3%, even as the ride-hailing firm gave an upbeat gross bookings forecast for the September quarter. Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Eli Lilly beats earnings for second quarter on strong GLP-1 sales, but stock dives on GLP-1 pill trial results
Eli Lilly (LLY) reported better than expected earnings for the second quarter Thursday. But disappointing results of its much-awaited oral pill GLP-1 sent its stock down in early trading. The stock is down 4% year-to-date, even as the sales of its blockbuster GLP-1s drive growth. Lilly reported $15.56 billion in revenues, beating Wall Street estimates of $14.69 billion. And earnings per share came in at $6.31 compared to Street expectations of $5.56. Revenue in the US alone was $10.81 billion, driven by a 46% increase in volume of sales of GLP-1s, Mounjaro and Zepbound, but the potential revenues could have been higher if not for an 8% decline in prices, according to Lilly. Though the pharma giant has a diverse portfolio of sales drivers, attention has been placed on the competitive GLP-1 space, as its weight loss drug Zepbound has overtaken competitor and first-mover, Novo Nordisk's (NVO) Wegovy. The latest GLP-1 prescription data tracked by JPM analysts shows Zepbound up 225% year over year, with total weekly prescriptions, as of the end of July, at more than 418,000 — compared to Wegovy's 35% year over year growth and 281,000 total weekly prescriptions. Meanwhile, what investors had viewed as the next ace in its pipeline, a GLP-1 pill, orforglipron, disappointed in late-stage trials Thursday. The company reported a 25% patient drop-out at the highest dose. "The discontinuation rate on the placebo was also quite high (press release says 29%), which makes us think there was something about the study that is odd/unique and will need to get some clarity here. To have this many patients drop out across arms is surprising and almost does not compute," said Mizuho's healthcare expert Jared Holz. The pill has been inching towards an FDA decision. The data for the pill will be filed with the FDA this year, and Lilly expects it could get to market by next year. Lilly's results come a day after disappointing results from Novo, which has faced pressure from compounders as well as the competition from Lilly. Novo revised its 2025 outlook down, to account for slower US sales. Lilly, meanwhile, has seen strong growth. Especially with new prescriptions of GLP-1s in the US moving more favorably toward Lilly — more than 60% of new weight loss prescriptions are for Zepbound, according to the latest data tracked by analysts. CEO Dave Ricks said in a statement, "Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
19 minutes ago
- Business Wire
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC ('Melinta'), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announces that it has entered into a definitive agreement to be acquired by CorMedix Inc. ('CorMedix') (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The acquisition is a testament to the exceptional value Melinta has created through its strong portfolio, culture, capabilities, and experienced team within the hospital ecosystem for acute care. 'This acquisition represents a milestone achievement for Melinta and validates our position as a recognized leader in acute care,' said Christine Ann Miller, CEO of Melinta Therapeutics. 'I'm incredibly proud of our accomplishments. Through our talented team's dedication, we have undergone an extraordinary transformation to build a highly sought-after commercialization platform with sustainable growth and profitability. By joining forces with CorMedix, we're creating a stronger organization that will accelerate both our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision that all patients who need our therapies receive them.' Since becoming privately owned by affiliates of healthcare investment firm Deerfield Management Company, L.P. in 2020, Melinta has demonstrated exceptional organizational evolution across operations, culture, and strategic positioning to achieve 85% revenue growth, positive cash flow, and sustainable profitability, while increasing employee satisfaction and building a highly talented team. Melinta has strengthened its position with global presence through ex-US partnerships and seven business development deals, including strategic partnership with BARDA to advance two FDA-approved antibiotics for use in pediatric patients, as well as the development of one product for use against biothreat pathogens. i This comprehensive evolution has established Melinta as a preferred partner who is fully integrated within the hospital ecosystem. This acquisition will expand CorMedix's commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO ® (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV ® (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate) ii. The portfolio's flagship product, REZZAYO ® is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation (BMT), which is expected to be completed in 1H2026. The addition of Melinta's high-performing team, innovative assets, and a pipeline expansion indication positions CorMedix to deliver on its ambition of becoming a leader in the specialty pharmaceutical business. 'The combination of CorMedix and Melinta represents a compelling opportunity to create a specialty pharmaceutical leader with enhanced capabilities to serve patients,' said Joseph Todisco, Chief Executive Officer of CorMedix Inc. 'Melinta's proven commercial platform and portfolio perfectly complement our own, and once combined we will have the scale, resources, and expertise to accelerate innovation while creating significant value for our stakeholders. We are thrilled to welcome the talented Melinta team and look forward to building on our shared commitment to excellence in this space.' 'Under Christine's leadership, the transformation of Melinta has been remarkable,' said Jonathan Leff, Board Member of Melinta and Partner at Deerfield Management Company. 'Through focused execution and strategic investment in its commercial capabilities, the Melinta team has built a high-performing organization that has consistently exceeded expectations. The combination with CorMedix reflects the strategic value of Melinta's infrastructure and positions the combined company for continued growth under Joe's leadership. We look forward to this next chapter.' Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay Melinta $300 million in upfront consideration (subject to customary adjustments), comprised of $260 million in cash and $40 million in CorMedix equity (in the form of pre-funded warrants) issued to Melinta shareholders. The agreement also contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix's election) for the FDA approval of REZZAYO ® for prophylaxis of invasive fungal infections in adults undergoing allogenic BMT, if the milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO U.S. net sales and low-single-digit royalties on MINOCIN ® for injection U.S. net sales. The merger is subject to customary closing conditions and U.S. regulatory approval and is expected to close in September. Advisors Evercore is acting as exclusive financial advisor and Fenwick & West LLP is acting as legal advisor to Melinta. Katten Muchin Rosenman LLP is acting as legal advisors for Deerfield Management Company, L.P. About Melinta Therapeutics Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that's how we make the most meaningful impact. At Melinta, we're visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), MINOCIN ® (minocycline) for Injection, ORBACTIV ® (oritavancin), REZZAYO ® (rezafungin for injection), TOPROL-XL ® (metoprolol succinate) and VABOMERE ® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, including their important safety information, visit About REZZAYO ® (rezafungin for injection) REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data. REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. IMPORTANT SAFETY INFORMATION REZZAYO is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins. REZZAYO may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion. REZZAYO may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation. Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO therapy. Most common adverse reactions (incidence 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. Please see the full Prescribing Information for REZZAYO (rezafungin for injection), available at
